BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 17172831)

  • 1. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis.
    Clifford SC; Lusher ME; Lindsey JC; Langdon JA; Gilbertson RJ; Straughton D; Ellison DW
    Cell Cycle; 2006 Nov; 5(22):2666-70. PubMed ID: 17172831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid diagnosis of medulloblastoma molecular subgroups.
    Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
    Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours.
    Goschzik T; Zur Mühlen A; Kristiansen G; Haberler C; Stefanits H; Friedrich C; von Hoff K; Rutkowski S; Pfister SM; Pietsch T
    Neuropathol Appl Neurobiol; 2015 Feb; 41(2):135-44. PubMed ID: 24894640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
    Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
    J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
    Kool M; Korshunov A; Remke M; Jones DT; Schlanstein M; Northcott PA; Cho YJ; Koster J; Schouten-van Meeteren A; van Vuurden D; Clifford SC; Pietsch T; von Bueren AO; Rutkowski S; McCabe M; Collins VP; Bäcklund ML; Haberler C; Bourdeaut F; Delattre O; Doz F; Ellison DW; Gilbertson RJ; Pomeroy SL; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):473-84. PubMed ID: 22358457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
    Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
    PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.
    Ellison DW; Onilude OE; Lindsey JC; Lusher ME; Weston CL; Taylor RE; Pearson AD; Clifford SC;
    J Clin Oncol; 2005 Nov; 23(31):7951-7. PubMed ID: 16258095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
    Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
    Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting the genomic complexity underlying medulloblastoma.
    Jones DT; Jäger N; Kool M; Zichner T; Hutter B; Sultan M; Cho YJ; Pugh TJ; Hovestadt V; Stütz AM; Rausch T; Warnatz HJ; Ryzhova M; Bender S; Sturm D; Pleier S; Cin H; Pfaff E; Sieber L; Wittmann A; Remke M; Witt H; Hutter S; Tzaridis T; Weischenfeldt J; Raeder B; Avci M; Amstislavskiy V; Zapatka M; Weber UD; Wang Q; Lasitschka B; Bartholomae CC; Schmidt M; von Kalle C; Ast V; Lawerenz C; Eils J; Kabbe R; Benes V; van Sluis P; Koster J; Volckmann R; Shih D; Betts MJ; Russell RB; Coco S; Tonini GP; Schüller U; Hans V; Graf N; Kim YJ; Monoranu C; Roggendorf W; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; von Deimling A; Witt O; Maass E; Rössler J; Ebinger M; Schuhmann MU; Frühwald MC; Hasselblatt M; Jabado N; Rutkowski S; von Bueren AO; Williamson D; Clifford SC; McCabe MG; Collins VP; Wolf S; Wiemann S; Lehrach H; Brors B; Scheurlen W; Felsberg J; Reifenberger G; Northcott PA; Taylor MD; Meyerson M; Pomeroy SL; Yaspo ML; Korbel JO; Korshunov A; Eils R; Pfister SM; Lichter P
    Nature; 2012 Aug; 488(7409):100-5. PubMed ID: 22832583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
    Korshunov A; Sahm F; Zheludkova O; Golanov A; Stichel D; Schrimpf D; Ryzhova M; Potapov A; Habel A; Meyer J; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
    Neuro Oncol; 2019 Feb; 21(2):214-221. PubMed ID: 30252101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics.
    Fattet S; Haberler C; Legoix P; Varlet P; Lellouch-Tubiana A; Lair S; Manie E; Raquin MA; Bours D; Carpentier S; Barillot E; Grill J; Doz F; Puget S; Janoueix-Lerosey I; Delattre O
    J Pathol; 2009 May; 218(1):86-94. PubMed ID: 19197950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Clinical and Molecular Wnt and SHH Subgroups in Medulloblastoma Tumor Cases.
    Kaya IS; Aksoy S; Mutlu M; Tekin C; Taskapilioglu MO; Tunca B; Civan MN; Ocak PE; Kocaeli H; Bekar A; Egeli U; Cecener G; Tolunay S
    Turk Neurosurg; 2021; 31(4):554-565. PubMed ID: 33978203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
    Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
    Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.
    Pugh TJ; Weeraratne SD; Archer TC; Pomeranz Krummel DA; Auclair D; Bochicchio J; Carneiro MO; Carter SL; Cibulskis K; Erlich RL; Greulich H; Lawrence MS; Lennon NJ; McKenna A; Meldrim J; Ramos AH; Ross MG; Russ C; Shefler E; Sivachenko A; Sogoloff B; Stojanov P; Tamayo P; Mesirov JP; Amani V; Teider N; Sengupta S; Francois JP; Northcott PA; Taylor MD; Yu F; Crabtree GR; Kautzman AG; Gabriel SB; Getz G; Jäger N; Jones DT; Lichter P; Pfister SM; Roberts TM; Meyerson M; Pomeroy SL; Cho YJ
    Nature; 2012 Aug; 488(7409):106-10. PubMed ID: 22820256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis.
    Hui AB; Takano H; Lo KW; Kuo WL; Lam CN; Tong CY; Chang Q; Gray JW; Ng HK
    Clin Cancer Res; 2005 Jul; 11(13):4707-16. PubMed ID: 16000565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of Ror2 and Wnt5a expression in medulloblastoma.
    Lee SE; Lim SD; Kang SY; Suh SB; Suh YL
    Brain Pathol; 2013 Jul; 23(4):445-53. PubMed ID: 23278988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
    Zhukova N; Ramaswamy V; Remke M; Martin DC; Castelo-Branco P; Zhang CH; Fraser M; Tse K; Poon R; Shih DJ; Baskin B; Ray PN; Bouffet E; Dirks P; von Bueren AO; Pfaff E; Korshunov A; Jones DT; Northcott PA; Kool M; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognár L; Cho BK; Eberhart CG; Conter CF; Fouladi M; French PJ; Grajkowska WA; Gupta N; Hauser P; Jabado N; Vasiljevic A; Jung S; Kim SK; Klekner A; Kumabe T; Lach B; Leonard JR; Liau LM; Massimi L; Pollack IF; Ra YS; Rubin JB; Van Meir EG; Wang KC; Weiss WA; Zitterbart K; Bristow RG; Alman B; Hawkins CE; Malkin D; Clifford SC; Pfister SM; Taylor MD; Tabori U
    Acta Neuropathol Commun; 2014 Dec; 2():174. PubMed ID: 25539912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medulloblastomas in adults: prognostic factors and lessons from paediatrics.
    Fellay CN; Frappaz D; Sunyach MP; Franceschi E; Brandes AA; Stupp R
    Curr Opin Neurol; 2011 Dec; 24(6):626-32. PubMed ID: 22027544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.